HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma

Files in This Item:
IntJClinOncol22_181.pdf973.76 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/68250

Title: Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma
Other Titles: Expression of p53, p16, cyclin D1, EGFR and Notch1 in patients with the temporal bone squamous cell carcinoma
Authors: Morita, Shinya Browse this author
Nakamaru, Yuji Browse this author →KAKEN DB
Homma, Akihiro Browse this author →KAKEN DB
Yasukawa, Shinichiro Browse this author
Hatakeyama, Hiromitsu Browse this author →KAKEN DB
Sakashita, Tomohiro Browse this author →KAKEN DB
Kano, Satoshi Browse this author →KAKEN DB
Fukuda, Atsushi Browse this author
Fukuda, Satoshi Browse this author →KAKEN DB
Keywords: Temporal bone squamous cell carcinoma
Clinicopathological features
EGFR
Protein expression
Immunohistochemistry
Prognostic factor
Issue Date: Feb-2017
Publisher: Springer
Journal Title: International Journal of Clinical Oncology
Volume: 22
Issue: 1
Start Page: 181
End Page: 189
Publisher DOI: 10.1007/s10147-016-1026-5
PMID: 27488595
Abstract: Background: The aim of this study was to investigate the expression of p53, p16, cyclin D1, epidermal growth factor receptor (EGFR) and Notch1 in temporal bone squamous cell carcinoma (TBSCC) tissue samples by immunohistochemistry (IHC), and to evaluate the association between these biomarkers and clinicopathological features. Methods: We performed a retrospective, single-institution review of 30 TBSCC patients treated with curative intent between April 2006 and March 2015. All tissue samples were obtained from pretreatment biopsy specimens or surgical specimens and using IHC staining. Results: Ten patients were categorized as T1, seven as T2, five as T3 and eight as T4. Nine patients had clinically positive lymph node metastasis. The positive expression of p53 and EGFR was significantly associated with T classification (P = 0.042 and P = 0.0039). EGFR expression was significantly more frequent in patients with positive lymph node metastasis compared with patients without node involvement (P = 0.017). In the analysis of the association between protein expression by IHC staining and prognosis, the positive expression of EGFR and Notch1 was significantly correlated with poor survival outcomes in TBSCC (P = 0.015 and P = 0.025) Conclusion: Overexpression of p53 and EGFR may be valuable biomarkers for identifying individuals at high risk of developing tumors in TBSCC. Furthermore, the positive expression of EGFR was significantly associated with poor survival outcome. Anti-EGFR therapy has potential for use as the treatment modality of choice for advanced-stage TBSCC as well as other head and neck squamous cell carcinomas.
Rights: The final publication is available at Springer via http://dx.doi.org/10.1007/s10147-016-1026-5
Type: article (author version)
URI: http://hdl.handle.net/2115/68250
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 森田 真也

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University